Frontlight ResearchEarly access
Taking people in United StatesPhase 3
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Key facts
- Who runs it
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Where
- Boston, Columbus, El Paso, Greenville, Indianapolis, Morehead City, Philadelphia, and Reno, United StatesSee the 8 sitesAlso in 3 other countries, 4 sites
- Trial code
- NCT07805356
- EU 2026-526140-13-00
- U1111-1341-6994
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 160 people, planned
- Started
- 31 Aug 2026
- Expected to end
- Jan 2033
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Encaleret
- Placebo
- Record updated
- 12 November 2026
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Participants must have had a clinically confirmed diagnosis of chronic HP, with disease duration of at least 26 weeks prior to screening. Cause of chronic HP can be postsurgical, autoimmune, genetic, or idiopathic
- For participants with nonsurgical chronic HP etiology, sufficient documentation that the participant does not harbor any variants in calcium-sensing receptor (CASR) or GNA11 that are classified as pathogenic, likely pathogenic, or of uncertain significance, with the exception of benign common polymorphisms (CASR A986S and R990G) is needed
- Participants must be on stable doses of calcium and active vitamin D supplementation at or above the following minimum thresholds for at least 6 weeks prior to screening; For participants enrolled in study sites outside Japan:
- Calcitriol ≥0.5 micrograms (μg)/day or alfacalcidol ≥1.0 μg/day
- Elemental calcium ≥800 milligrams (mg)/day (for example, calcium citrate, calcium carbonate)
- Participants must meet the following criteria during screening: cCa within 7.8 to 9.5 mg/deciliter (dL) and 24-hour UCa ≥300 mg/day (males) or ≥250 mg/day (females)
- Participants have serum 25-hydroxy (OH) vitamin D concentration of 20 to 80 nanograms (ng)/milliliter (mL) (50-200 nanomoles [nmol]/liter [L])
- Participants have serum magnesium concentration within the reference range
- Participants on thiazide or loop diuretics must be able to discontinue them during the first 24 weeks of study (treatment)
- Participants must be capable of giving signed informed consent or assent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
Who cannot take part
- History of hypocalcemic seizure in the 3 months prior to screening
- Prior skeletal irradiation, chemotherapy with alkylating agents, or diagnosis of Paget's disease, fibrous dysplasia, chronic osteomyelitis, bone infarcts, benign bone tumors with curettage and grafting, retinoblastoma, or Li-Fraumeni syndrome
- History of cancer (except thyroid cancer, non-melanoma skin cancer) or bone metastases in the 5 years prior to screening
- Presence or history of any disease or condition (for example, drug or alcohol dependence) that, in the view of the investigator, would affect the participant's safety or places the participant at high risk of poor treatment compliance or of not completing the study; Other protocol-defined inclusion/exclusion criteria apply
- Genetically confirmed diagnosis of autosomal dominant hypocalcemia type 1 (ADH1) or autosomal dominant hypocalcemia type 2 (ADH2) due to activating variants in CASR or GNA11, respectively
Where in United States
Also in 3 other countries, 4 sites
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteBoston, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteColumbus, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteEl Paso, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteGreenville, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteIndianapolis, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteMorehead City, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SitePhiladelphia, United StatesTaking people
- Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational SiteReno, United StatesTaking people
About the trial
What the trial wants to find out
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
The 2 groups in the trial
- EncaleretTreatment being tested
Participants will receive encaleret during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label long-term extension (LTE) period to continue receiving encaleret for up to 192 weeks.
- PlaceboPlacebo, for comparison
Participants will receive placebo during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label LTE period to receive encaleret for up to 192 weeks.
Treatment: Encaleret and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Investigating Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
- Record updated
- 12 November 2026